Civic AI
Civic AI
Procurement intelligence
SAM.govHT9402-26-Q-9303
Open

Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

DEPT OF DEFENSE · TX
Response deadline
Jun 29, 2026
Closed
Date posted
Jun 8, 2026

Description

The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following August 2026 newly approved drugs will be reviewed: a. Bysanti - Antipsychotic Agents - Atypical b. Idvynso - Antiretrovirals - Combinations c. Nereus - Antiemetic-Antivertigo Agents – N/A d. Zolymbus - Glaucoma Agents - Prostaglandin The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9303. Pre-quotation teleconference is on June 10, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POCs in Part 2.3.1., no later than the date stated in Part 2.3.2.

Classifications

Documents (8)

  • Price List - Bysanti - Antipsychotic Agents - Atypical.xlsx
    .xlsx45 KB
    Download
  • RFQ HT9402-26-Q-9303 NAD.pdf
    .pdf790 KB
    Download
  • https://health.mil/PandT
    Not yet available
  • Price List - Nereus - Antiemetic-Antivertigo Agents - NA.xlsx
    .xlsx45 KB
    Download
  • Price Appendix FAQ NAD.pdf
    .pdf231 KB
    Download
  • Price List - Idvynso - Antiretrovirals - Combinations.xlsx
    .xlsx44 KB
    Download
  • DoD Formulary Placement of FDA Newly Approved Drugs.pdf
    .pdf83 KB
    Download
  • Price List - Zolymbus - Glaucoma Agents - Prostaglandin.xlsx
    .xlsx45 KB
    Download

Contacts

Explore more